BMS terminates collaboration with uniQure effective Feb 21, 2023

uniQure N.V.

Bristol-Myers Squibb provided termination notice for collaboration and license agreement originally dated May 2015.
Termination is effective February 21, 2023; the agreement was amended in December 2020.
BMS did not replace any of the four active Collaboration Targets during the one-year option period.
A change-of-control payment of up to $70M to BMS is still contingent; no such transaction has occurred.
The separate Investor Agreement between uniQure and BMS remains in force per its terms.

item 1.02 item 8.01

Key facts

Extracted from this filing and checked against the source text.

Material Agreements SEC 8-K Item 1.01/1.02 confidence 1.0

uniQure N.V. terminated BMS CLA with Bristol-Myers Squibb (effective 2023-02-21).

Action: termination
Agreement: license
Counterparty: Bristol-Myers Squibb
Effective: 2023-02-21

Exact text from the filing

On November 21, 2022, BMS provided, and the Company received, a notice that the BMS CLA, as amended, will terminate effective February 21, 2023 (the “Termination Notice”).

View on SEC.gov

Browse all material agreements →

uniQure N.V. filing history →

Source: SEC EDGAR

accession 0001104659-22-122454

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.